Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$5.4 million.
- Vivos Therapeutics' Net Income towards Common Stockholders fell 10642.2% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.2 million, marking a year-over-year decrease of 3608.75%. This contributed to the annual value of -$11.2 million for FY2024, which is 1784.82% up from last year.
- According to the latest figures from Q3 2025, Vivos Therapeutics' Net Income towards Common Stockholders is -$5.4 million, which was down 10642.2% from -$5.0 million recorded in Q2 2025.
- Vivos Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$1.7 million for Q1 2023, and its period low was -$7.4 million during Q4 2021.
- In the last 5 years, Vivos Therapeutics' Net Income towards Common Stockholders had a median value of -$4.3 million in 2023 and averaged -$4.4 million.
- As far as peak fluctuations go, Vivos Therapeutics' Net Income towards Common Stockholders tumbled by 16430.23% in 2021, and later soared by 6805.48% in 2023.
- Quarter analysis of 5 years shows Vivos Therapeutics' Net Income towards Common Stockholders stood at -$7.4 million in 2021, then grew by 17.64% to -$6.1 million in 2022, then grew by 29.35% to -$4.3 million in 2023, then surged by 32.94% to -$2.9 million in 2024, then plummeted by 87.18% to -$5.4 million in 2025.
- Its Net Income towards Common Stockholders was -$5.4 million in Q3 2025, compared to -$5.0 million in Q2 2025 and -$3.9 million in Q1 2025.